Moderna’s Cancer-Vaccine Leak Spurs Panic Selling. Wall Street Wanted a Cure.

Moderna, Meta, SpaceX, Bloom Energy, AT&T, and More Stocks That Explain Today’s Market

Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip

Merck CEO Plays Down Cost Concerns Over Intismeran — ‘We Don't See Cost As A Limit To Access’

Iovance’s Melanoma Therapy Shows Promising 4-Year Data – Retail Says Acquisition Imminent Before 2027-End

AbbVie’s Dividend Survived Humira’s Patent Cliff. Will Merck and Amgen’s?

Merck And Moderna Diverge On Cancer Vaccine Results. Do They Still Have A Viable Drug?

Moderna stock extends losses as investors digest melanoma vaccine trial data

Can Merck (MRK) Stay Undervalued If Cash Flow Keeps Growing?

Beyond Keytruda: The Critical Pipeline Metrics to Watch in Merck’s Q3 Results on Oct. 29